Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Fineline Cube Jul 7, 2026
Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Fineline Cube Jul 7, 2026
Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Fineline Cube Jul 7, 2026
Company Deals

CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand

Fineline Cube Jul 7, 2026
Company Deals

Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger

Fineline Cube Jul 7, 2026
Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026
Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company

Johnson & Johnson Reports H1 2023 Sales Growth Following Kenvue Spinoff

Fineline Cube Aug 31, 2023

Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has released a financial update for...

Company

Zhejiang Dian Diagnostics Reports 2023H1 Revenue Dip, Strategic Expansion Continues

Fineline Cube Aug 31, 2023

China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has released its financial report for the...

Company Deals

Novo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development

Fineline Cube Aug 31, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the purchase of compatriot Embark Biotech,...

Company Drug

Pfizer and BioNTech Receive Positive CHMP Opinion for Comirnaty Vaccine

Fineline Cube Aug 31, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

Dizal Pharmaceutical’s Golidocitinib Earns Priority Review for r/r PTCL Treatment in China

Fineline Cube Aug 30, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its drug golidocitinib has been...

Company Deals

Ronovo Surgical Secures Pre-Series B+ Funding to Advance Modular Surgical Robots

Fineline Cube Aug 30, 2023

Shanghai-based minimally invasive surgical robot developer, Ronovo Surgical, has reportedly raised close to RMB 200...

Company Drug

AIM Vaccine Co., Ltd Launches Phase III Trial for 23-Valent Pneumococcal Vaccine

Fineline Cube Aug 30, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the commencement of a Phase III...

Company Deals

Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies

Fineline Cube Aug 30, 2023

Shanghai-based Kangpu Biopharmaceuticals, Ltd has reportedly raised close to RMB 100 million (USD 13.8 million)...

Company Deals

Epigenic Therapeutics Secures $32 Million in Series A Funding for Gene Modulation Therapy

Fineline Cube Aug 30, 2023

Epigenic Therapeutics, a Shanghai-based biotech company specializing in gene modulation therapy through epigenome regulation, has...

Company Deals

Biocytogen Pharmaceuticals’ Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies

Fineline Cube Aug 30, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd’s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced...

Company Drug

CSPC Pharmaceutical’s Biosimilar Ozempic Equivalent Gets NMPA Clinical Trial Approval

Fineline Cube Aug 30, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its biosimilar version of Novo...

Company Drug

Jiangsu Yahong Meditech Gets NMPA Approval for APL1401 Ulcerative Colitis Trial

Fineline Cube Aug 30, 2023

Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer based in...

Company

Luye Pharma Group Reports H1 2023 Revenue Growth with Strong Oncology and CNS Sales

Fineline Cube Aug 30, 2023

China-based Luye Pharma Group (HKG: 2186) has announced its financial performance for the first half...

Company

Fosun Pharma Reports Moderate Revenue Growth and Increased R&D Spend in 2023 Interim Report

Fineline Cube Aug 30, 2023

Fosun Pharma (SHA: 600196) has released its 2023 interim financial report, recording revenues of RMB...

Company Drug

Roche’s Evrysdi Receives EC Approval for Expanded Indication in Infants with SMA

Fineline Cube Aug 30, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has received regulatory approval from the European Commission (EC)...

Company Drug

MSD’s Keytruda Gains EC Approval for First-Line HER2-Positive Gastric Cancer Treatment

Fineline Cube Aug 30, 2023

The European Commission (EC) has granted an additional indication to Merck, Sharp & Dohme (MSD;...

Company Drug

BMS’ Reblozyl Expands Indication to Include First-Line MDS-Related Anemia Treatment

Fineline Cube Aug 30, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has received an indication extension approval from the US Food...

Company Policy / Regulatory

HHS Releases List of 10 Drugs for Medicare Price Negotiations Starting 2026

Fineline Cube Aug 30, 2023

The Department of Health and Human Services (HHS) in the US has released a list...

Company Drug

ImmunoTech Biopharm’s EAL Earns Breakthrough Therapy Designation for HCC Recurrence Prevention

Fineline Cube Aug 29, 2023

The Center for Drug Evaluation (CDE) in China has indicated on its website that Immunotech...

Company Deals

Mabwell Bioscience Secures Deal with UNILAB for Biosimilar Humira in the Philippines

Fineline Cube Aug 29, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a licensing and supply agreement...

Posts pagination

1 … 506 507 508 … 691

Recent updates

  • China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development
  • Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development
  • Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio
  • Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project
  • CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.